2021
Psychotherapy-supported MDMA treatment for PTSD
Krystal JH, Kelmendi B, Petrakis IL. Psychotherapy-supported MDMA treatment for PTSD. Cell Reports Medicine 2021, 2: 100378. PMID: 34467253, PMCID: PMC8385322, DOI: 10.1016/j.xcrm.2021.100378.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyHumansMedicineN-Methyl-3,4-methylenedioxyamphetaminePsychotherapyStress Disorders, Post-Traumatic
2003
Preliminary evidence of hippocampal dysfunction in adolescent MDMA (“ecstasy”) users: possible relationship to neurotoxic effects
Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH. Preliminary evidence of hippocampal dysfunction in adolescent MDMA (“ecstasy”) users: possible relationship to neurotoxic effects. Psychopharmacology 2003, 173: 383-390. PMID: 14647960, DOI: 10.1007/s00213-003-1679-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAttentionFemaleHippocampusHumansMagnetic Resonance ImagingMaleMemoryN-Methyl-3,4-methylenedioxyamphetamineSerotonin AgentsVerbal BehaviorConceptsFunctional magnetic resonance imagingMDMA usersCognitive deficitsMDMA useBrain functionDivided attentionMemory taskMemory loadResultsMDMA usersLeft hippocampusHippocampal dysfunctionSubstance useCognitive impairmentAdolescencePreliminary evidenceReaction timeDevelopmental impactPilot sampleDeficitsMDMAMagnetic resonance imagingIQAttentionMemoryHippocampus
1992
Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use: Effects on Mood and Neuropsychological Function?
Krystal J, Price L, Opsahl C, Ricaurte G, Heninger G. Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use: Effects on Mood and Neuropsychological Function? The American Journal Of Drug And Alcohol Abuse 1992, 18: 331-341. PMID: 1357957, DOI: 10.3109/00952999209026070.Peer-Reviewed Original ResearchMeSH Keywords3,4-MethylenedioxyamphetamineAdultCognition DisordersDepressive DisorderFemaleHumansMaleMiddle AgedNeuropsychological TestsN-Methyl-3,4-methylenedioxyamphetamineSerotoninSubstance-Related DisordersWechsler ScalesConceptsNeuropsychological functionMDMA useChronic MDMA useWechsler Memory ScaleLeast mild impairmentMemory ScaleNeuropsychological batteryTime of testingMood effectsCognitive functionMemory deficitsMethylenedioxymethamphetamine (MDMA) useDepressed moodMood regulationPreliminary evidenceDeficitsMild impairmentClinical criteriaClinical examinationPreliminary findingsSelective serotoninMoodModerate impairmentAffective disordersPossible detrimental effects
1989
Neuroendocrine and Mood Responses to Intravenous L-Tryptophan in 3,4-Methylenedioxymethamphetamine (MDMA) Users: Preliminary Observations
Price LH, Ricaurte GA, Krystal JH, Heninger GR. Neuroendocrine and Mood Responses to Intravenous L-Tryptophan in 3,4-Methylenedioxymethamphetamine (MDMA) Users: Preliminary Observations. JAMA Psychiatry 1989, 46: 20-22. PMID: 2562914, DOI: 10.1001/archpsyc.1989.01810010022003.Peer-Reviewed Original ResearchResponses to i.v. L-tryptophan in MDMA users.
Price LH, Ricaurte GA, Krystal JH, Heninger GR. Responses to i.v. L-tryptophan in MDMA users. NIDA Research Monograph 1989, 95: 421-2. PMID: 2577044.Peer-Reviewed Original Research3,4-MethylenedioxyamphetamineAdultAffectAmphetaminesDesigner DrugsFemaleHumansMaleN-Methyl-3,4-methylenedioxyamphetamineProlactinReceptors, SerotoninSubstance-Related DisordersTryptophan